Open AccessScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
Author(s) -
Bart M. Demaerschalk,
Dawn Kleindorfer,
Opeolu Adeoye,
Andrew M. Demchuk,
Jennifer E. Fugate,
James C. Grotta,
Alexander A. Khalessi,
Elad I. Levy,
Amy Yu,
Shyam Prabhakaran,
Gustavo Saposnik,
Jeffrey L. Saver,
Eric E. Smith
Publication year - 2015
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/str.0000000000000086
Subject(s) - medicine , stroke (engine) , inclusion (mineral) , inclusion and exclusion criteria , alternative medicine , clinical trial , family medicine , fibrinolytic agent , tissue plasminogen activator , pathology , mechanical engineering , gender studies , sociology , engineering
To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of alteplase and improve outcomes after stroke.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom